Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Chronic stable angina,Vasospastic angina (Prinzmetal's angina),Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
92-98% bound to serum albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
1.0-1.5 L/kg; large distribution suggests extensive tissue penetration.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Immediate-release: 40-60% (extensive first-pass metabolism); sustained-release: 80-90% relative to immediate-release formulation.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No specific dose adjustment required; use caution in severe renal impairment (GFR <30 m L/min).
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh Class A: reduce dose by 50%; Class B or C: contraindicated or use with extreme caution, reduce dose by 60-75%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Not FDA-approved for pediatric use; off-label: 0.25-0.5 mg/kg/dose orally every 6-8 hours, maximum 3 mg/kg/day.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Initiate at lower doses (e.g., 10 mg immediate-release 3 times daily or 30 mg XL once daily); titrate slowly; monitor for hypotension and edema.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA-issued black box warning.
None
May cause severe hypotension especially with concomitant beta-blockers,Peripheral edema,Gingival hyperplasia,Hepatic impairment may require dose adjustment,Avoid abrupt discontinuation (may worsen angina),Increased risk of myocardial infarction in patients with coronary artery disease
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Acute myocardial infarction (within first 4 weeks),Concomitant use with strong CYP3A4 inducers or inhibitors
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Grapefruit juice and grapefruit increase the AUC and Cmax of nifedipine by approximately 2-fold due to CYP3A4 inhibition; avoid concurrent consumption. Alcohol may exacerbate hypotension and vasodilatory effects. High-fat meals can delay absorption of extended-release tablets but do not significantly alter overall bioavailability.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second and third trimesters: Associated with reduced uteroplacental blood flow, fetal hypoxia, and low birth weight. Tocolysis use may cause maternal hypotension and fetal distress. Overall, FDA Category C.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Nifedipine is excreted into breast milk; milk-to-plasma ratio approximately 1.0. Low relative infant dose (2-5% of maternal weight-adjusted dose). No reported adverse effects in breastfed infants. However, caution is advised, especially in preterm or low-birth-weight infants. Monitor infant for hypotension or adverse effects.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No standard dose adjustment required. However, increased clearance and volume of distribution in pregnancy may require dose titration to achieve clinical effect. Start with lowest effective dose.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Nifedipine (Procardia) is a dihydropyridine calcium channel blocker with potent vasodilatory effects. Avoid sublingual administration of short-acting capsules due to risk of profound hypotension, myocardial ischemia, and stroke. Use only extended-release formulations for chronic hypertension or stable angina. May cause peripheral edema; differentiate from heart failure. Gingival hyperplasia can occur with chronic use. Contraindicated in patients with a history of hypersensitivity to dihydropyridines, cardiogenic shock, significant aortic stenosis, or within 4 weeks of myocardial infarction.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit juice and grapefruit products as they increase nifedipine levels and risk of toxicity.,Report persistent swelling of ankles/feet, severe headaches, dizziness, or palpitations to your healthcare provider.,Rise slowly from sitting or lying positions to minimize orthostatic hypotension.,Practice good oral hygiene and regular dental check-ups to reduce risk of gum overgrowth.,Do not stop taking this medication abruptly; taper under medical supervision to avoid rebound angina.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA vs ADALAT, answered by our medical review team.
PROCARDIA is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA is: Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA is classified as Category C. First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second an. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.